Altogether, these results suggest that PRMT3 is a previously unknown IFNγ-responsive gene that was up-regulated by anti-PD-1/PD-L1 therapy in HCC and may play a role in the anti-tumor immunity and the adaptive response to ICB. The gene discussed is IFNG; the disease is neoplasm.